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Abstract The therapeutic value of antibiotics depends on the susceptibility of the infecting
microorganism and the pharmacological profile of the drugs. To assess the value of an
antibiotic combination of polymyxin B and miconazole this study examined the in vitro
synergistic potential of the two drugs on Gram-negative and Gram-positive bacteria and
yeast. Antifungal and antibacterial activity was tested by minimum inhibitory concentration
(MIC) of broth macrodilution and urea broth microdilution, by fluorescence microscopy
and flow cytometry. Synergism was calculated using the fractional inhibitory concentration
index (FICi). With Staphylococcus intermedius as target we found up to an eightfold
reduction of the individual MICs when both drugs were combined. However, the FICi was
0.63 suggesting no real interaction between the two drugs. With Escherichia coli,
Pseudomonas aeruginosa, and Malassezia pachydermatis as targets the antimicrobial drug
combination reduced the MICs of polymyxin B and miconazole from fourfold to
hundredfold resulting in FICi between 0.06 and 0.5 which defines a synergistic action.
Thus, if polymyxin B and miconazole are combined their effect is greater than the sum of
the effects observed with polymyxin B and miconazole independently, revealing
bactericidal and fungicidal synergism. Our results indicate a strong therapeutic value for
the combination of these antimicrobial agents against Gram-negative bacteria and yeast and
a weaker value against Gram positive bacteria for clinical situations where these pathogens
are involved.
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Polymyxin B is an amphipatic cyclic decapeptide and cationic detergent with a broad
antibiotic spectrum. It effects against Gram-negative bacteria such as Enterobacter,
Escherichia coli, Pseudomonas spp., Salmonella spp. and Shigella spp and to a lesser
extent, against Gram-positive bacteria as Staphylococcus spp. and Streptococcus spp. The
bactericidal effect of polymyxin B relies on a dual mechanism of action. The sublethal
action occurs as polymyxin B binds to the outer membrane of bacteria where it complexes
avidly with lipopolysaccharides (Newton 1954) and disorganizes the whole outer
membrane (Hancock 1984; Koike et al. 1968; Nikaido and Vaara 1985). This allows
polymyxin B to enter the cytoplasmic membrane where it causes leakage of cytoplasmic
components entailing the cells to die. It is noteworthy that the membrane permeability
changes immediately on contact with the drug. The activity of polymyxin B is antagonized
by Mg
2+ and Ca
2+ (Newton 1953), thus part of the action of this antibiotic is assumed as
competitively displacing Mg
2+ or Ca
2+ from the negatively charged phosphate groups of
membrane lipids. On parenteral administration polymyxin B is extreme nephrotoxic.
However, as it completely lacks absorption from intact skin or mucous membrane and thus
produces no systemic reaction, it is applied hitherto almost exclusively in topical therapy.
Yet the polymyxins gain increasingly importance as reserve antibiotic. As the emergence of
multiresistent Gram-negative bacteria pose serious clinical problems the polymyxins are
recommended for severe systemic infections caused by bacteria that are resistant to other
antibiotics (Ouderkirk et al. 2003; Pasquale and Tan 2005).
Miconazole, another antimicrobial active substance also aims at interacting with the
cytoplasma membrane of microbiological pathogens. Miconazole belongs to the chemical
class of imidazoles with a broad antifungal spectrum against most of the pathogenic fungi
and Candida albicans. In vitro it shows an effect against some Gram-positive germs and
acanthamoeba, too (Janssen and Van Bever 1979; McEvoy 1992). The drug permeates the
chitin of the fungal cell wall and increases the membrane permeability to various
intracellular substances (Sreedhara Swamy et al. 1974). Miconazole is known to interfere
with the synthesis of fungal and bacterial lipid membranes as it restrains the synthesis of
ergosterol which results in accumulation of toxic methylated sterol intermediates in
membranes and subsequently in fungal cell growth arrests (Vanden Bossche et al. 1990).
Another mode of miconazole antifungal action is the induction of reactive oxygen species
in susceptible fungi leading to fungal cell death (Francois et al. 2006; Kobayashi et al.
2002). Side effects are rare if miconazole is applied topically (Sawyer et al. 1975) and to
date no resistances are known in animals to miconazole (McEvoy 1992).
The application of both polymyxin B as an antibiotic and miconazole as a fungicide and
Gram-positive antibacterial agent is common for those infections, where fungal and
bacterial pathogens are aetiological. Both antimicrobial agents are proposed for the
treatment of systemic mycosis and have been combined so far in topical preparations to
provide a complementary antimicrobial spectrum for the prevention of minor wound
infections and the treatment of dermatitis or otitis externa in veterinary medicine (Kiss et al.
1997; Rougier et al. 2005; Studdert and Hughes 1991). Organisms frequently isolated from
these lesions include E. coli, P. aeruginosa, S. intermedius and the lipophilic yeast M.
pachydermatis. The latter is a common inhabitant of the outer ear duct in dogs and cats but
can also become an opportunistic pathogen, where an infectious state usually parallels a
primary established illness.
The combination of antibiotics may reveal positive drug interactions such as an
enhanced activity of the compounds or an increased antimicrobial spectrum. Several studies
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agent polymyxin B and specific antibiotics (Rosenthal and Storm 1977), (Richards and
Xing 1993), (Booth et al. 1994). Many studies have documented that polymyxin B
nonapeptide which lacks bactericidal activity but has an outer membrane–permeabilization
action preserved induces an increase in sensitivity to different antibiotics and other drugs
(for review see (Vaara 1992)). The potentiation of the antifungal activity of tetracycline by
polymyxin B through selective alteration of cell membrane permeability was reported, too
(Schwartz et al. 1972), however there are contradictory results on this interaction. Also the
lysis of Neisseria catarrhalis and other Gram-negative bacteria by lysozyme has been
demonstrated in cells pretreated with polymyxin B sulfate. Since neither polymyxin nor
lysozyme acting independently on the cells resulted in lysis, these results suggested that
pre-treatment with the antibiotic increased the permeability of the cells or disorganized the
cell wall and hence rendered the mucopolysaccharide substrate accessible to the action of
the enzyme (Warren et al. 1957). Furthermore the antibacterial activity of a combination of
miconazole and/or bacitracin with polymyxin B against Staphylococcus aureus and E. coli
was higher than the sum of the effects observed with the two drugs independently
(Cornelissen and Van den Bossche 1983). A synergy in antifungal activity against Candida
albicans was reported as well when polymyxin B was combined with amphotericin B,
ketoconazole and miconazole (Moneib 1995) and miconazole applied together with
benzoylperoxide markedly increased the bactericidal activity against Staphylococcus spp.
and Propionibacterium acnes (Vanden Bossche et al. 1982).
It was the objective of the study to verify the presumed synergistic effect of polymyxin
B and miconazole with both bacteria and yeast. We compared the in vitro activity of
polymyxin B and miconazole as single substances and in combination against E. coli, P.
aeruginosa, S. intermedius and M. pachydermatis. Bacterial viability was assessed by
means of a standard MIC test, fluorescence microscopy and flow cytometry while yeast
susceptibility was evaluated using an urea broth microdilution method.
Materials and methods
Antimicrobial agents
Freshly prepared solutions of polymyxin B sulfate (Sigma-Aldrich, Taufkirchen, Germany)
in deionized water or miconazole nitrate salt (Sigma-Aldrich) dissolved in 25% (v/v)
ethanol and 75% (v/v) polyethylenglycol 400 while heating for 2 h at 60°C were filter
sterilized (pore size 0.2 μm) prior use.
Susceptibility testing
For examination of antibiotic susceptibility the tube dilution test was applied. The quality
control strains E. coli (ATCC 25922), P. aeruginosa (ATCC 27853) and S. intermedius
(ATCC 5739) were used for determination of MICs. For the content of selected tubes from
susceptibility testing we determined the minimal bactericidal concentration (MBC) by
endpoint colony counting of bacteria on Mueller-Hinton agar. For pre-trial MIC E. coli
strain XL-1 (Stratagene) was used. E. coli and P. aeruginosa were cultivated in Mueller-
Hinton Broth (Merck/VWR, Darmstadt, Germany; if not mentioned otherwise, all
chemicals were obtained from Merck/VWR). S. intermedius was propagated either in
corynebacteria nutrient (1% casein peptone, tryptic digest, Difco/BD, Heidelberg, Germany,
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Bacteria from frozen stocks were subcultured three times on agar plates. Then two single
colonies were picked each to inoculate a liquid overnight culture. The bacterial cultures
were grown to early log phase at 37°C aerobically by shaking in a reciprocating shaker.
Bacterial inoculum was prepared in Mueller-Hinton Broth at 2×10
6 colony forming units
(CFU)/ml to give a final concentration of 2×10
6 CFU. To each tube 5.0 ml of bacterial
culture, 4.0 ml of growth medium, 0.5 ml of a polymyxin B dilution or 0.5 ml of a dilution
of miconazole was added. Each 0.5 ml of dilution of polymyxin B and miconazole was also
added in combination to 5.0 ml of bacterial culture and 4.0 ml of growth medium. Samples
with single active substance or controls were adjusted to a total volume of 10.0 ml with
0.5 ml sterile deionized water. Solutions of polymyxin B or miconazole consisted of log10
dilution steps between 750 and 0.075 μg/ml and log2 dilution steps between 750 and
0.046 μg/ml. For all experiments freshly prepared antimicrobial solutions were used.
Bacterial cultures without active substance (C, bacterial inoculum and growth medium)
and bacterial cultures with 0.5 ml solvent (L, bacterial inoculum, growth medium and
solvent containing 25% ethanol and 75% polyethylenglycol 400, which was also heated to
60°C for 2 h) served as growth controls. Also a sterility control tube (M, growth medium)
was included into each MIC test. The cultures were incubated for 18 h at 37°C under
aerophilic conditions. After 18 h of incubation the MIC was read as the lowest drug
concentration that inhibited bacterial growth.
Each test was performed 5 times. For the first clear tube containing both antimicrobial
agents the fractional inhibitory concentration (FIC) was calculated as follows: FIC of drug
A (FICA) = MIC of drug A in combination/MIC of drug A alone, FIC of drug B (FICB)=
MIC of drug B in combination/MIC of drug B alone. FIC Index (FICi), calculated as the
sum of each FIC, was interpreted as follows: FICi ≤ 0.5 = synergy, FICi > 4.0 = antagonism
and FICi > 0.5–4 = no interaction (Odds 2003).
Christensen’s urea broth microdilution method
The Christensen’s urea broth microdilution method (Nakamura et al. 2000) (Rincón et al.
2006) was applied to assay the antifungal activities of polymyxin B and miconazole alone
and in combination against M. pachydermatis. With this test fungal cell activity is
measured. The mechanism is relying upon the release of ammonia during urea hydrolysis to
change the pH of the medium, converting the yellow phenol red indicator to pink (Roberts
et al. 1978).
Malassezia. pachydermatis reference strain (CBS 1879) was propagated at 35°C on
modified Leeming and Notman slants (Leeming and Notman 1987) containing 1%
bacteriological peptone (Difco/BD), 1% glucose, 0.2% yeast extract (Difco/BD), 0.8% ox
bile (Difco/BD), desiccated, 1% (v/v) glycerol (Sigma-Aldrich, Taufkirchen, Germany),
glycerol monostearate (Elbe Fetthandel GmbH, Geesthacht, Germany), 0.5% (v/v) Tween
60 (Sigma-Aldrich), 2% olive oil (Sigma-Aldrich) and 1.5% agar (Sigma-Aldrich). The
isolate was subcultured every 2 weeks more than three times before use. The colonies were
collected by scraping, suspended with sterile 0.04% Tween 80 in sterile deionized water (pH
7.4) with a glass homogenizer and the suspension was adjusted to an OD at 530 of 0.42 to
0.43 (∼1×10
6 CFU/ml). Solutions of polymyxin B or miconazole consisted of log2 dilution
steps between 187.5 and 0.01 μg/ml. The urea broth microdilution method was performed
in 96-well microtiter plates. Christensen’s urea broth contained 0.1% peptone (Difco/BD),
0.0012% phenol red (Sigma-Aldrich), 0.5% sodium chloride, 0.2% monopotassium
phosphate, 0.1% glucose, 2% urea, supplemented with 0.1% Tween 80 (Sigma-Aldrich)
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urea broth, 50 μl yeast suspension, 25 μl test drug and 25 μl sterile deionized water or
50 μl test drug and no water if both test drugs were used in combination. The final
inoculum of Malassezia pachydermatis in each well was ∼0.25×10
5 CFU/ml.
The test drugs were arranged in twofold dilution from left to right and in triplicate. The
96-well microtiter plates were sealed with Parafilm® M and incubated at 35°C for 48 h. The
results were evaluated visually. The MICs were defined as the lowest drug concentration at
which there was complete inhibition of growth and no colour change of the media was
observed.
Fluorescence microscopy
To differentiate live bacteria from dead ones, bacteria were stained in suspension with the
Live/Dead BacLight Bacterial Viability Kit (Molecular Probes, Mobitek, Germany). The
SYTO 9 nucleic acid stain solution (excitation/emission maxima 480/500) is cell-permeable
and stains RNA and DNA in both live and dead bacterial cells green. Propidium iodide (PI,
excitation/emission maxima 490/635) penetrates only cells with damaged membranes, thus
stains the cells red. Logarithmically growing bacteria cultures were incubated with dilutions
of polymyxin B, miconazole or with both substances in combination for 18 h at 37°C while
agitation. Each 1.5 ml bacterial sample was concentrated by centrifugation at 10.000×g for
5 minutes at room temperature and washed once with 0.9% NaCl. The supernatant was
removed and the pellet resuspended in 150 μl 0.9% NaCl. SYTO9 dye (3.34 mM in
anhydrous dimethylsulfoxide, DMSO) and PI dye (20 mM in anhydrous DMSO) were
combined 1:1 and mixed thoroughly. To each 150 μl of concentrated bacterial suspension
0.8 μl of the dye mixture was added, mixed and incubated in the dark at room temperature
for 15 minutes. Five μl of the stained bacterial suspension was transferred onto a 24×
46 mm coverslip and visualized directly using a confocal laser scanning microscope
Olympus FluoView™ FV1000 (Olympus, Hamburg, Germany). Confocal images were
obtained with an argon ion laser as excitation source (excitation wavelength of 488 nm;
1.3% laser power), which was reflected by an dichroic mirror (DM 351/488/543) and
focused onto the sample through an oil immersion objective (Olympus Planapochromat 60 x,
numerical aperture NA=1.35. Detection channels were set to fluorescein isothiocyanate
(FITC, maximum emission 515 nm) and Alexa 594 (maximum emission 618 nm). The live
(green fluorescent) and dead (red fluorescent) cells are shown separately and as an overlay
with FITC and Alexa 594 bandpass filters. For virtual magnification of bacteria a 3-fold
digital zoom was applied.
Bacteria were also visualized with a Zeiss Axiovert 10 microscope (Zeiss, Oberkochen,
Germany) equipped with filter set 00 (BP530-585, FT600, LP615) and filter set 09 (BP450-
490, FT 510, LP515).
Flow cytometry
Data were acquired with a FC 500 flow cytometer (Beckman Coulter) with an argon ion
laser at 488 nm and 20 mW output. Data acquisition and analysis were controlled using
Cytomics software. The emission light path contained a 488 nm blocking filter, a 525
bandpass filter before the photomultiplier 1 (PMT) and a 620 nm bandpass filter before the
PMT3. The density of the bacterial suspensions was 1×10
6 CFU/ml. Bacterial suspensions
were incubated with dilutions of polymyxin B, miconazole or both substances in
combination for 18 h at 37°C at aerobic conditions. The cells were harvested by
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670 nm of 0,03 with 0.9% NaCl. Then 6 μl of 1:1 SYTO9 and PI dye mixture was added to
2 ml of diluted bacterial suspension, mixed well and incubated in the dark at room
temperature for 15 min. Populations of bacteria were discriminated as two regions of the
log-integrated red-fluorescence (FL3) versus log-integrated green fluorescence (FL1) plot.
The percentage of bacteria found within the region identified as those with the "live" cell
population was used to estimate the percentage of viable organisms. Using the known
viability (proportion of "live" to "killed" bacteria) and measured viability (measured % live
bacteria = [# of bacteria in the "live" region/# of bacteria in the "live"+"dead" region]×100)
and a least-squares fit extrapolated to the 100% "live" point the percent component of dead
bacteria in the "live" cell population was estimated.
Results
Antibiotic susceptibility
MICs of two antimicrobials given as single drug each or in combination were determined.
The results of the susceptibility tests are summarized in Table 1. E. coli strain XL-1 was
susceptible to 7.5 μg/ml polymyxin B, but was susceptible to a concentration of polymyxin
B as low as 0.07 μg/ml if combined with 0.07 μg/ml miconazole (FICi=0.01). No effect on
bacterial growth was observed it miconazole was applied alone. The E. coli quality control
strain was susceptible to 2.93 μg/ml polymyxin B if given as a single antibiotic and to a
concentration of 0.18 μg/ml if applied together with the identical concentration of
miconazole (FICi=0.06). As well miconazole alone could not inhibit E. coli growth. P.
aeruginosa was susceptible to 0.73 μg/ml polymyxin B and showed no effect to
miconazole. If polymyxin B acted together with miconazole each drug was inhibitory at
a concentration of 0.18 μg/ml (FICi=0.25). Thus, when polymyxin B and miconazole were
applied in combination they reproducibly showed a clear synergistic antibacterial effect
against the Gram-negative strains tested. The Gram-positive S. intermedius was susceptible
to 0.73 μg/ml miconazole and to 2.93 μg/ml polymyxin B. If identical concentrations of
polymyxin B and miconazole were combined a twofold lower dose of miconazole and an
Table 1 In vitro susceptibilities of bacterial and yeast strains
Germ strain Miconazole MIC*
Range (Mode)
Polymyxin B MIC
Range (Mode)
Miconazole+ Polymyxin B
MIC Range (Mode) FICi
E. coli XL-1
a no inhibition 7.50 < 0.07 0.01
E. coli (ATCC 25922)
b no inhibition 0.73 – 2.93 (2.93) 0.18 – 1.46 (0.18) 0.06
P. aeruginosa (ATCC 27853)
b no inhibition 0.73 0.18 – 0.37 (0.18) 0.25
S. intermedius (ATCC 5739)
b 0.37 – 7.5 (0.73) 2.93 – 7.50 (2.93) 0.37 – 0.75 (0.37) 0.63
M. pachydermatis (CBS1879)
c 2.92 – 5.85 (2.92) 2.92 – 23.43 (2.92) 0.37 – 1.46 (0.73) 0.50
*MIC, minimal inhibitory concentration, given in µg/ml; FICi, fractional inhibitory concentration index,
given as described in Material and methods
a Results of 2 repeated experiments on different days
b Results of 5 repeated experiments on different days
c Results of 5 repeated experiments on different days with triplicates of each sample
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FICi=0.63). According to a recent revision of the definition of synergy a FICi > 0.5–4.0 is
interpreted as ‘no interaction’ (Odds 2003). Therefore the resulting FICi of 0.63 indicates
there is no interaction between both drugs if active against S. intermedius.
The mean antifungal activies of miconazole and polymyxin B against M. pachydermatis
were measured using an urease method, as shown in Fig. 1. If we compared the wells
Fig. 1 Antifungal MIC determi-
nation using Christensen’s urea
broth microdilution method. Urea
hydrolysis by M. pachydermatis
in microtiter test plates. A
positive test is read as a colour
change from yellow to pink. The
test drugs were arranged in
twofold dilution from left to right
(row 1-12, 188 μg/ml to
0.09 μg/ml) and in triplicate
(rows A, B, C). D1, D4, E1, E4,
F 1 and F4 represent negative
controls (growth medium with
distilled water). D2, E2 and F2
are positive controls (all
compounds without test drug).
D3, E3, F3 contain the solvent of
miconazole (polyethylenglycol
400 with ethanol), growth
medium and yeast cells as a
growth control.
From top to bottom: Plate with
dilutions of polymyxin B. Plate
with dilutions of miconazole.
Plate with dilutions of micona-
zole plus polymyxin B
Vet Res Commun (2009) 33:489–505 495containing the growth media without M. pachydermatis to drug-containing wells with yeast
cells we found a MIC of 2.92 μg/ml for miconazole and for polymyxin B as well. If both
antimicrobial agents were given in combination susceptibility of M. pachydermatis changed
to a MIC of 0.73 μg/ml (FICi=0,50), which indicates a synergistic response.
Confocal laser scanning microscopy and fluorescence microscopy
Qualitative differentiation of live and dead bacteria was done by confocal laser scanning
microscopy (CLSM). CLSM is non-destructive and makes it possible to analyze live
biological samples. Living and dead microorganism could be detected in situ using an
appropriate staining method. Cultures of S. intermedius were incubated with different
concentrations of polymyxin B and miconazole and stained subsequently with SYTO9 and
PI dye. The analysis of bacteria by CLSM allowed the generation of images where the
fluorescence of only one dye was visualized. Using narrow bandpass filters the
fluorescence of one or the other dye was eliminated respectively. Imaging from the green
emission only detects the living green cells and imaging from the red emission detects the
dead red cells solely. The left and the right pictures of Fig. 2 represent identical shots of
bacterial S. intermedius suspensions. The untreated bacteria (2-1 and 2-2) with only a few
red (dead) cells are shown in (2-2). After 18 h of incubation with 75 μg/ml miconazole (2-3
and 2-4) more than 50% of the cells became red and are assumed to be dead or in the
process to die (2-4). The application of an identical concentration of polymyxin B (2-5 and
2-6) resulted in about 50% red cells (2-6). A tenfold lower concentration of both
antimicrobials applied in combination (2-7 and 2-8) revealed strikingly more red cells (2-8)
than miconazole or polymyxin B generated when applied alone (2-4 and 2-6, respectively).
Toexhibitbothdyeswithinonepictureanoverlayoftwoimages,eachdetectedwithanarrow
fluorescence wavelength range was made. Thus the living and dead cells of Fig. 2 are visualized
within one image (Fig. 3). Consequently, using CLSM and the Live/Dead BacLight Bacterial
Viability Kit the live and the dead organisms can be differentiated and determined even after
they had been mixed. Furthermore it was possible to evaluate the antibiotic effect visually.
Live and dead bacteria were also visualized with an inverted fluorescence microscope
after staining with SYTO9 and PI dye. With this method green and red cells are
discriminated using alternately a filter set for FITC and other green fluorochromes or a filter
set for red fluorochromes. Owing to the fact that these bandpass filters are not as narrow as
in CLSM the pictures representing the green fluorescence also show red cells in the
background. If red cells overlay green cells these cells are visualized yellow. Figure 4
demonstrates a qualitative analysis of antimicrobial action against E. coli and P. aeruginosa
after 18 h of antibiotic action. Cells without treatment show very few red bacteria (a, e);
following application of 0.73 μg/ml miconazole alone about 10% cells are scored as dead
(red) (b, f). An identical concentration of solitary polymyxin B gave rise to about 30% dead
(red) cells (c, g) whereas a fourfold lower concentration of each drug, if applied in
combination, produced a comparable biological effect (d, h). As a result using this method
the antibiotic effectiveness can be quickly evaluated qualitatively as a ratio of live and dead
cells within a given population. Visual examination of bacterial cells has approved an
enhanced bacterial killing if miconazole and polymyxin B are applied together.
Flow cytometry
Exemplified on two bacterial strains we analysed E. coli and P. aeruginosa by flow
cytometry after antibiotic exposure and staining with the Live/Dead BacLight Bacterial
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standard curve shown in Fig. 5. For E. coli the rate of live cells was 87% and for P.
aeruginosa we identified 98% live cells within the population investigated.
When E. coli was treated with 2.93 μg/ml of miconazole, a dead rate of 10.9% was
measured which is in the dimension of the normal proportion of dead cells within a
poulation. On the other hand 2.93 μg/ml of polymyxin B resulted in killing of 45.8% E.
coli bacteria. Both drugs in combination each at a concentration of 1.46 μg/ml killed 72.0%
Fig. 2 Confocal laser scanning
microscopy. Samples of
S. intermedius after treatment for
18 h with polymyxin B,
miconazole or with both poly-
myxin B and miconazole in
combination. The cells were
stained with SYTO 9 and PI. The
left (green) pictures are generated
using a FITC bandpass filter and
visualize only the living cells,
whereas the right (red) pictures
are generated from identical
presentations using an Alexa 594
bandpass filter to detect the dead
cells exclusively.
From top to bottom: Untreated
bacteria (2-1 and 2-2). Bacteria
treated with 75 μg/ml miconazole
(2-3 and 2-4). Bacteria treated
with 75 μg/ml polymyxin B
(2-5 and 2-6). Bacteria treated
with 7.5 μg/ml miconazole plus
7.5 μg/ml polymyxin B
(2-7 and 2-8)
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18 h flow cytometric analysis of the vitality of P. aeruginosa revealed that less cells were
affected. After application of 5.86 μg/ml miconazole 8.1% of the bacterial population
stained red and therefore was counted dead while 5.86 μg/ml of polymyxin B resulted in
only 5.7% dead cells. The combination of 2.93 μg/ml miconazole with 2.93 μg/ml
polymyxin B stained 27% of the cells red (results are not shown) which is decidedly a
lower rate of dead cells than that found with E. coli. Our results show that the survival rate
for the determination of bactericidal efficacy of antibacterial agents can be measured by
FACS analysis. Against E. coli and P. aeruginosa we could demonstrate an enhanced effect
when both the drugs miconazole and polymyxin B act in combination.
Discussion
This study was conducted to evaluate the net results of the in vitro interactions against
bacteria and yeast between polymyxin B and miconazole using different methods. While
for decades miconazole has been successfully applied as a very potent antifungal drug
polymyxin B has not been used over the past years but in veterinary medicine because less
toxic antimicrobials are available. Yet bacteria that are resistant to aminoglycosides, beta-
lactams and fluoroquinolones are becoming more common and these germs are often
susceptible to the polymyxins.
The tube dilution test for the determination of MICs against the two strains of E. coli,
against P. aeruginosa and against S. intermedius demonstrated that all the bacteria were
susceptible to polymyxin B. Data of our MIC tests are consistent with previous reports
where the MIC against E. coli was in the range of 0.4 to 37 μg/ml (Kucers 1997). Against
P. aeruginosa polymyxin B exhibited excellent potency. We found P. aeruginosa to be
more sensitive to polymyxin B compared to reported MICs which range from 1.2 to
Fig. 3 Overlay pictures of live
(green fluorescent) and dead (red
fluorescent) S. intermedius
bacteria are shown using a
confocal laser scanning
microscope.
Untreated bacteria (3-1). Bacteria
treated with 75 μg/ml miconazole
(3-2). Bacteria treated with
75 μg/ml polymyxin B (3-3).
Bacteria treated with 7.5 μg/ml
miconazole plus 7.5 μg/ml poly-
myxin B (3-4)
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intermedius to different antimicrobial agents. Though many authors quote the antimicrobial
activity of polymyxin B to be restricted to Gram-negative bacteria (e.g. Chambers 2001),
several studies showed the effectiveness of polymyxin B against S. intermedius. On the
other hand a low susceptibility of S. intermedius strains isolated from dogs to polymyxin B
was also reported (Junco and Barrasa 2002). In our study polymyxin was quite effective
against S. intermedius, our tests revealed a MIC of 5.21 μg/ml which is in a magnitude
comparable to the MICs of other bacterial strains investigated. It is noteworthy that
Fig. 4 Fluorescence microscopy
of E. coli (a, b, c, d) and P.
aeruginosa (e, f, g, h), treated
with either polymyxin B, mico-
nazole or with both substances in
combination for 18 h. Cells were
then stained with SYTO9 and PI.
Identical pictures of bacterial
suspensions are generated with a
green (left pictures) or red (right
pictures) filter set. The red
stained cells represent bacteria
with damaged membranes and
the green cells denote those with
intact membranes. Untreated
bacterial cells (a, e), bacteria
treated with 0.73 μg/ml
miconazol (b, f), with 0.73 μg/ml
polymyxin B (c, g) and with
0.18 μg/ml miconazole plus
0.18 μg/ml polymyxin B (d, h)
Vet Res Commun (2009) 33:489–505 499polymyxin B also showed activity against M. pachydermatis although the inhibitory
concentration of the drug was higher than those against the bacteria tested.
As expected from the known antimicrobial spectrum of miconazole the fungizide was
not inhibitory against the Gram-negative bacteria tested. Yet S. intermedius and the yeast M.
pachydermatis were both susceptible at a MIC of 0.73 and 2.92 μg/ml respectively. These
values are in agreement with corresponding studies who noticed concentrations of 0.1 to
10 μg/ml to be inhibitory against Gram-positive bacteria and many fungi including M.
furfur (McEvoy 1992). With most of the sensitive fungi a MIC of 0.5 to 2.0 μg/ml was
reported. However it should be kept in mind that the exactness of in vitro miconazole
Fig. 4 (continued)
500 Vet Res Commun (2009) 33:489–505susceptibility testing depends on the measuring method and MIC values do not reflect the
activity in vivo.
The MIC values derived from our tube dilution tests showed some variation. This may
be due to the fact that cations such as Mg
2+,A l
3+, and Ca
2+ can adversely affect the activity
of antimicrobials. Several investigators have related increased resistance of P aeruginosa to
aminoglycosides with increased concentrations of Mg
2+ and Ca
2+ in the media and
conversely the antibacterial activity of aminoglycoside antibiotics was shown to be
enhanced in media with low cationic content (D’Amato et al. 1975). Variations of these ions
within lot-to-lot variation in Mueller-Hinton broth may be responsible for varying
susceptibilities (Pollock et al. 1978). As well the activity of miconazole is affected by the
medium composition as the effect of miconazole was notedly reduced even by very low
concentrations of Mg
2+ and Ca
2+ cations (Sreedhara Swamy et al. 1974).
In CLSM analysis of drug action against S. intermedius we found a much higher dose of
miconazole and polymyxin B to be necessary for a visual bactericidal effect. Presumably
due to the thick cell wall of Gram-positive bacteria this strain reacted much slower to
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Fig. 5 Analysis of bacterial cells by flow cytometry. The known viability (proportion of ‘live’ to ‘killed’
bacteria) is plotted against the measured viability to identify the percent component of dead bacteria in the
‘live’ cell population
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502 Vet Res Commun (2009) 33:489–505miconazole and polymyxin B than Gram-negative cells and thus much higher drug doses
were necessary to demonstrate a killing effect within 18 h. On the other hand at the
concentration, where a dilution of miconazole or polymyxin B caused bacteriostasis we
detected only small differences in drug susceptibility between the Gram-positive and the
Gram-negative bacteria.
The quantitative measurement of vital and dead cells after antibiotic action by means of
flow cytometry was evaluated. When bacteria are treated with drugs that are assumed to
change cell permeability this may also affect intracellular granularity and cell morphology
and may encompass cell clumping as well. Measurement of antibiotic effects by flow
cytometry detects such cellular changes through forward and side scatter. The loss of light
scatter may delineate a change in cell size and could also represent a loss of cell wall
constituents such as protein or RNA. This is likely to occur with the antibiotics used here.
We found that regions are shifted after cells are exposed to polymyxin B and miconazole.
Thus, for discrimination between live and dead cells we had to rearrange the regions after
antibiotic exposure.
It was also noticed that miconazole at concentrations >11 μg/ml a high percentage of E.
coli cells stained red with PI (97.4%) and 18.1% of P. aeruginosa cells became red after an
identical dose of miconazole. Data from the tube dilution tests however demonstrated that
this concentration of miconazole could neither inhibit growth of E. coli nor of P.
aeruginosa. MBC assaying of those miconazole-exposed bacteria approved that the PI-
stained cells were all able to recover and to reproduce. Obviously under the condition of
solitary miconazole application bacterial membranes are compromised allowing PI to
penetrate into the cells and thus bacteria are falsely scored as dead in this assay. However,
the lethal action is solely attained if miconazole is applied together with polymyxin B. In
accordance to the data above miconazole is known to change the membrane permeability at
fungistatic concentrations (Sawyer et al. 1975, McEvoy 1992) while at fungicide
concentrations the cell wall remains intact but intracellular compounds are destroyed
(McEvoy 1992). As a result, the analysis of antimicrobial activity by flow cytometry or
fluorescence microscopy using PI staining is possible although there are some restrictions
concerning specific drugs such as miconazole, which may produce false results at certain
concentrations. Consequently each drug to be analysed using this method should be
pretested conducting precedent MBC testing on representative samples.
The combination of miconazole and polymyxin B produced synergistic inhibition of
several germs at various in vitro conditions in our hands. On the basis of our data the
antimicrobial activity of miconazole and polymyxin B was enhanced in all strains tested
when both drugs are combined. Synergy refers to the phenomenon where the combination
of drugs generates an effect that is greater than the sum of the effects produced by each of
the components alone (Sabath 1968). This synergistic activity is related predominantly to
the ability of polymyxin B to increase the penetration of hydrophobic antibiotics such as
miconazole thus enabling miconazole to gain access to the intracellular space were it
Fig. 6 Live/dead discrimination of E. coli after incubation with either polymyxin B, miconazol or both
substances in combination for 18 h. Cells were analysed by flow cytometry using a double colour staining
consisting of SYTO9 and PI. Dot plots on the left show the whole cell populations, where green dots
represent live cells and red dots denote dead cells. Dot plots on the right illustrate the bacterial populations
separated into two regions B and C with B representing the dead cells (red, FL3), and C corresponding to the
living cell population (green, FL1). Cells in B and C are displayed as % of the total population A. E. coli
untreated (a), E. coli treated with 2,93 μg/ml miconazole (b), with 2.93 μg/ml polymyxin B (c), with
1.46 μg/ml miconazole plus 1.46 μg/ml polymyxin B (d)
R
Vet Res Commun (2009) 33:489–505 503displays its lethal action. The results we obtained with the combination of miconazole and
polymyxin B in all strains tested consistently showed a synergism of both drugs. Our results
are in agreement with previous in vitro studies where a synergism of miconazole and
polymyxin B was found for S. aureus, E. coli (Cornelissen and Van den Bossche 1983) and
C. albicans Provided the in vitro antibacterial susceptibility predicts therapeutic response
these data verify the potential for the use of combinations of the two antimicrobial agents in
the topical treatment of infections caused by the prominent pathogenic microorganisms
causative for otitis externa in dogs. The clear synergistic tendencies displayed by the two-
drug combination allows for the reduction of the antibiotic concentrations, which minimizes
toxicity and the probability of formation of resistances to these antibiotics. This may be of
special interest in the case of S. intermedius which, ensuing antimicrobial therapy, is
increasingly reported to be resistant to many antibiotics and failures in treatments cause
problems in small animal practice. As a consequence the combination of both
antimicrobials substantiates their clinical role in current formulations and offers a very
effective therapeutic treatment.
Open Access This article is distributed under the terms of the Creative Commons Attribution
Noncommercial License which permits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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